A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin - Trial NCT06323161
Access comprehensive clinical trial information for NCT06323161 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Recruiting. The study focuses on Type 2 Diabetes. Target enrollment is 270 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novo Nordisk A/S
Timeline & Enrollment
Phase 3
Mar 26, 2024
Nov 04, 2025
Primary Outcome
Change in Glycated Haemoglobin (HbA1c)
Summary
This study will look at how much CagriSema helps people with type 2 diabetes lower their
 blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet
 prescribe CagriSema. CagriSema will be compared to a dummy medicine (also called placebo)
 that has no effect on the body. Participant will get either CagriSema or dummy medicine and
 which treatment they get is decided by chance. Participant will take the study medicine
 together with their current diabetes medicine (once-daily insulin with or without metformin).
 For each participant, the study will last for about one year.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06323161
Non-Device Trial